Healio

Ensifentrine improves outcomes in COPD, but unlikely to be cost effective

Please provide your email address to receive an email when new articles are posted on . Ensifentrine plus maintenance therapy yielded multiple benefits in patients with moderate to severe COPD. If ...
The American Journal of Managed Care

FDA Approves Ensifentrine for Maintenance Treatment of Adult Patients With COPD

Today, the FDA approved ensifentrine (Ohtuvayre; Verona Pharma) for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD) based on the successful phase 3 ENHANCE ...
Monthly Prescribing Reference

Nebulized Ensifentrine Significantly Improves Lung Function, COPD Symptoms

Credit: Getty images The ENHANCE-1 trial evaluated nebulized ensifentrine as monotherapy or as an add-on to a LAMA or a LABA in patients with moderate to severe COPD. Treatment with nebulized ...
Healio

Ensifentrine improves dyspnea, symptoms, quality of life in COPD without exacerbations

Please provide your email address to receive an email when new articles are posted on . This analysis focused on adults with moderate to severe COPD without an exacerbation during the ENHANCE trials.
Monthly Prescribing Reference

Ensifentrine Improves Lung Function, Cuts COPD Exacerbations in Late Stage Trial

Credit: Getty Images. Ensifentrine (RPL554) is a first-in-class, dual phosphodiesterase (PDE) 3 and 4 inhibitor with combined bronchodilator and anti-inflammatory actions. Treatment with nebulized ...
The American Journal of Managed Care

Ensifentrine Shows Promise as Add-On, Stand-Alone Therapy in COPD: M. Bradley Drummond, MD, MHS

M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill, shares promising results of ensifentrine in helping patients with insufficient chronic obstructive ...
manilatimes

Nuance Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-CHINA Trial for COPD

The investigational study drug, ensifentrine is a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 ("PDE3; PDE4") that combines bronchodilator and non-steroidal anti-inflammatory ...